600276.SH
恒瑞医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 46.76
−2.05%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
34.0x
EV/EBITDA
26.8x
Market Cap
CNY 310.36B
MomentumView details →
1D Return
−2.05%
YTD Return
−22.75%
RSI (14)
32.6
ValuationView details →
P/E (Fwd)
34.0x
EV/EBITDA
26.8x
Market Cap
CNY 310.36B
RSI (14)
32.6
MomentumView details →
1D Return
−2.05%
YTD Return
−22.75%
Similar companies
Latest newsMore news →
Hengrui Medicine announced that its subsidiary Guangdong Hengrui Medicine received an acceptance notice from China's National Medical Products Administration for the marketing authorization application of its self-developed drug Zhuotuoqibei monoclonal antibody injection (SHR-1819), intended for treating moderate-to-severe atopic dermatitis in adults.1d agoHengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical received acceptance from China's National Medical Products Administration for the marketing authorization application of HRS-7535 tablets, a novel oral small-molecule GLP-1R agonist for type 2 diabetes.2d agoHengrui Pharmaceuticals announced that its subsidiary Suzhou Shengdiya Biopharmaceutical's ADC drug Ruikang trastuzumab (SHR-A1811) met the primary endpoint in a Phase III clinical trial for first-line treatment of HER2-positive advanced breast cancer, and the company plans to submit a pre-marketing communication application to the CDE.4d ago